Држава: Јапан
Језик: Енглески
Извор: すりの適正使用協議会 RAD-AR Council, Japan
Adalimumab(genetical recombination) [adalimumab biosimilar 4]
NIPPON KAYAKU
Adalimumab(genetical recombination) [adalimumab biosimilar 4]
colorless to faintly yellowish brown and limpid or slightly opalescent injectable solution in a prefilled syringe with an injection needle contained inside a pen device for single use
Drug Information Sheet("Kusuri-no-Shiori") Self-injection Published: 11/2023 The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment. BRAND NAME: ADALIMUMAB BS SUBCUTANEOUS INJECTION 40MG PEN 0.4ML "CTNK" ACTIVE INGREDIENT: Adalimumab(genetical recombination) [adalimumab biosimilar 4] DOSAGE FORM: colorless to faintly yellowish brown and limpid or slightly opalescent injectable solution in a prefilled syringe with an injection needle contained inside a pen device for single use IMPRINT OR PRINT ON WRAPPING: EFFECTS OF THIS MEDICINE This medicine suppresses function of TNF (tumor necrosis factor)-α, which is one of the possible primary causative substances in rheumatoid arthritis, psoriasis, ankylosing spondylitis, juvenile idiopathic arthritis, Crohn's disease and ulcerative colitis. TNF is one of the cytokines existing inside of the body even in a healthy state, and involved in activities of immunity and development of inflammation or pain. It is usually used to treat rheumatoid arthritis (including prevention of structural joint damage) and diseases described below with inadequate response to conventional therapies: active polyarticular-juvenile idiopathic arthritis; psoriasis vulgaris/psoriasis arthritis/pustular psoriasis; ankylosing spondylitis; intestinal Behcet's disease; non-infectious intermediate/posterior uveitis or panuveitis; and moderate to severe ulcerative colitis. It is also used for inducing clinical remission and maintenance therapy in patients with moderately to severely active Crohn's disease. THE FOLLOWING PATIENTS MAY NEED TO BE CAREFUL WHEN USING THIS MEDICINE.BE SURE TO TELL YOUR DOCTOR AND PHARMACIST. ・If you have previously experienced any allergic Прочитајте комплетан документ